ADA and Erythema: Anti-TNFα agents, particularly ADA, followed by UST and VED, play a role in the onset of dermatological pathologies, including urticaria, erythema, and dermatitis [57]; moreover, our data showed a higher incidence of malignancies with VED when adjusted on 10 years of treatment.